GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
ATLANTA, GA - June 17, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today highlighted new clinical data presented at the 2025 European Hematology Association (EHA) Hybrid Congress, which took place June 12-15 in Milan, Italy.
The data were featured in a poster presentation by Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center in Duarte, California. The poster titled 'MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study', detailed findings from an ongoing randomized Phase 2 clinical trial (NCT05672355), and highlighted interim results showing superior cellular immune responses induced by GEO-CM04S1 compared to those induced by an authorized mRNA-based COVID-19 vaccine in CLL patients, a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction.
Key Findings from the Study
'These findings reinforce the clinical and immunologic advantages of our multi-antigen approach,' said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. 'GEO-CM04S1's robust cellular response in immunocompromised individuals, especially patients with hematologic malignancies like CLL, provides further validation of our MVA platform's potential to address critical gaps in COVID-19 protection.'
About GEO-CM04S1
GEO-CM04S1 is a next-generation COVID-19 vaccine based on a synthetic Modified Vaccinia Ankara (MVA) vector. Unlike single-antigen vaccines, it expresses both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2, aiming to provide broader, cross-reactive, and more durable immunity. The vaccine is currently being evaluated in three Phase 2 clinical trials across various patient populations, including immunocompromised individuals and healthy adults.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Media Contact:
Jessica Starman
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Alcohol-related liver problems escalate in Wisconsin, especially for women, young people
Deaths from liver diseases that result from consuming too much alcohol are escalating dramatically in Wisconsin, and even more alarming, such diseases are showing up more in younger people. The numbers mirror national trends described in a June 11 study in JAMA Open Network, which found a "significant acceleration" in alcohol-associated liver disease deaths during and after the COVID-19 pandemic. Nationwide, such deaths increased nearly 9% annually between 2018 and 2022. In Wisconsin, deaths from cirrhosis of the liver — one of several liver diseases tied to alcohol consumption — rose 35% between 2019 and 2023, according to data from the Centers for Disease Control and Prevention. It's well-documented that Americans began drinking more during the pandemic, and coupled with Wisconsin's deeply entrenched drinking culture, experts worry about the toll they're seeing on people's physical health. Alcohol-related deaths generally, which include myriad other causes besides liver problems, increased three-fold in Wisconsin between 1999 and 2020, a January analysis from the Journal Sentinel found. But experts say multidisciplinary treatment, reduced stigma around alcohol use disorder, and a renewed emphasis on education and prevention could improve the situation. "I think the narrative often in Wisconsin is just, 'Oh, we're just big drinkers,' and that's all there is," said Maureen Busalacchi, director of the Wisconsin Alcohol Policy Project at the Medical College of Wisconsin. "The message is not that you can't drink at all. It's more, really think about it, and just drink less." More: Wisconsin's alcohol-related deaths more than tripled since 1999: See the data U.S. dietary guidelines for alcohol urge people of drinking age to limit consumption to one drink or fewer per day for women and two drinks or fewer per day for men. When people consume significant amounts of alcohol over a prolonged period of time, fat begins to turn up in the liver, and then scar tissue, which can lead to cirrhosis, said Dr. Rita German, a transplant hepatologist at UW Health in Madison. Many times, German said, liver disease symptoms such as jaundice, fever and confusion don't show themselves until the disease has progressed, making it harder to treat. Nearly 3,000 Wisconsinites died from alcohol-related liver diseases from 2019 to 2023, CDC data show. The large majority — 2,072 — were from cirrhosis. Deaths from most types of liver diseases due to alcohol consumption increased in those years, including alcoholic fatty liver and alcoholic hepatic failure in addition to cirrhosis. Deaths from alcoholic hepatitis fell slightly. Busalacchi called the numbers a huge concern. Most of these deaths are preventable, she contended. Doctors used to think of alcohol-related liver diseases as affecting people past middle age, German said. But increasingly, that age is dropping. At UW Health's multidisciplinary clinic for patients with such diseases, she said, the average age is now 45, and she's treated some as young as 25. More: Alcohol-related deaths in Wisconsin tripled since 1999. Will a new warning from the surgeon general slow the trend? That may seem to conflict with recent research showing young people, particularly Gen Z, drinking less. But while some are cutting back, those who do drink are drinking more heavily, Busalacchi said. And while alcohol use among Wisconsin high schoolers has generally decreased in recent years, more than one in 10 reported binge drinking in the last 30 days on the state's most recent Youth Risk Behavior Survey, done in 2023. The JAMA study noted, in particular, increases in alcohol-related liver disease deaths among adults ages 25-44. Deaths among women also increased disproportionately. Women absorb more alcohol into their bloodstream because they're generally smaller than men and because women's bodies have less gastric alcohol dehydrogenase, the enzyme that breaks down alcohol in the stomach, German said. Thus, they're at greater risk for liver damage. The Medical College of Wisconsin's liver transplant team reports younger and younger women needing transplants due to alcohol consumption, Busalacchi said. More: US to drop guidance to limit alcohol to one or two drinks per day, sources say To catch alcohol-related liver diseases earlier, German said, it's critical that patients be forthcoming about their alcohol use at the doctor's office. And for that to happen, she said, doctors must view alcohol use disorder for what it is — a disease, not a personal failing. People who are concerned about their alcohol consumption may also request an ultrasound of their liver, German said. From there, they can begin treatment if need be. She also sees the benefits in treatment that is comprehensive. At UW Health's clinic, patients not only see doctors like German who attend to the liver, but addiction specialists and counselors to treat underlying mental health conditions that can drive alcohol use. The clinic has treated between 250 and 300 people since it began in 2021. If it's caught in time, fat and scarring in the liver can be reversed by abstaining from alcohol, German said. Busalacchi's work continues to focus on changing societal perceptions on drinking culture. She sees encouraging signs around the state from communities that are offering more education about the consequences of excessive drinking, especially for youth. Some are taking a harder stance on age compliance checks for alcohol sales. Madeline Heim covers health and the environment for the Milwaukee Journal Sentinel. Contact her at 920-996-7266 or mheim@ This article originally appeared on Milwaukee Journal Sentinel: Wisconsin deaths from alcohol-related liver diseases sharply rise
Yahoo
an hour ago
- Yahoo
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To provide a brief context, ENFLONSIA happens to be a preventive, long-acting monoclonal antibody (mAb) which has been designed to offer direct, rapid, and durable protection through 5 months, a typical RSV season, with the same 105 mg dose irrespective of weight. Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person's hand holding a bottle of pharmaceuticals. However, ENFLONSIA should not be administered to infants who have a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of ENFLONSIA. Merck & Co., Inc. (NYSE:MRK) added that the approval is basis the results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants. Furthermore, the focus is to ensure the availability of ENFLONSIA in the US before the upcoming RSV season begins. This is to help in reducing the significant burden of the widespread seasonal infection on families and health care systems. Artisan Partners, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
2 hours ago
- Miami Herald
The Teen Mom is Dying Out
While the birth rate has declined in general over the last 50 years, mothers aged between 15 and 19 have seen the most consistently steep fall. In 1975, there were 599,926 teen births in America – more than double the teen pregnancies recorded in 2024 (136,376), according to the U.N. Population Division. Among the teen births that do take place today, "the vast majority occur among folks who are 18 or 19," said Elizabeth Wildsmith, a family demographer and sociologist at Child Trends, a nonpartisan research organization. "Teen births have declined dramatically over the past several decades," she told Newsweek, citing a lower level of sexual activity among teenagers, a higher level of contraceptive use and wider social changes. "No easy answers," said Claire Brindis, co-director of the Adolescent and Young Adult Health National Research Center at the University of California, San Francisco. "No one factor can really explain the reductions," she told Newsweek, citing similar reasons to Wildsmith, along with improved access to education. Brindis also drew on the general trend of having children later, currently taking place across all age groups. "We have to give young people a lot of credit for being pregnancy-free," she said. Some 32 percent of high schoolers said they had ever had sex in 2023, according to the Centers for Disease Control and Prevention's (CDC) most recent Youth Risk Behavior Survey (YRBS). This is a decrease from the 47 percent who said they had ever had sex a decade earlier, in 2013, and significantly lower than in 1991, when 54 percent said they had ever had sex. "I am not sure we have a clear understanding yet of the role that digital/social media is playing in shaping how and when youth form relationships, including sexual relationships, or their thoughts and behavior around parenthood," Wildsmith said. "There is likely a mix of positive and negative impacts. For example, online resources, especially reliable sources that use evidence-based information, may help youth learn about various contraceptive methods and more easily access them," she continued. "Similarly, they can provide access to content around what a safe and healthy romantic relationship looks like." "At the same time, we know that health misinformation on social media platforms is a serious concern," she added. She went on to align the decline in sexual activity with "a decline in the proportion of youth that have ever dated." Brindis also spoke about cultural shifts, pointing to the pandemic when she said: "Perhaps another factor is a residual of COVID, with more young people hanging out in groups, after long periods of isolation, and less likely to end up only in pairs." "Ironically, while more teens are exposed to pornography through social media, they are less likely to feel comfortable talking to each other and being in a relationship," she added. But she went on to speak about the impact of increased education and the choices this has provided. "Clearly, access to education has been shown to be a huge motivator," Brindis said, "as young women are surrounded by role models, including their moms, who have improved their own educational status and who hold great expectations that their daughters can break more glass ceilings than they were able to themselves." "Young women are more likely to explore how to protect themselves, including delaying having sex, having fewer partners, if they are sexually active (which reduces their risk as more steady partners will increase the likelihood of conversations about birth control protection in the context of all their other dreams," she added. While "the dramatic decline in the teen birth rate since the early 1990s has occurred across all race/ethnic and socioeconomic groups," as Wildsmith said, the declines "have been somewhat uneven across groups and there are still large disparities in the teen birth rate across race, ethnicity, and socioeconomic status." For example, teen birth rates among Native (20.9), Hispanic (20.8), Pacific Islander (21.2), and Black (19.3) teens were more than double that of white teens (8.4) and over ten times higher than Asian teens (1.8) in 2023, according to a Congressional Research Service report published in April, which used data from the National Center for Health Statistics. "We should recognize that there continues to be segments who are more likely to be at risk-young people who are poor or low income, those who live in rural communities, with less education, and with less hope for economic opportunities continue to be more vulnerable," Brindis said. "The risks are that we don't continue to invest in young people across all groups, and especially women, if education opportunities are shut off, if economic options (as an alternative to going to college), if student loans are eliminated or more difficult to get, if families have more economic struggles, if access to birth control or other social support services, for example, many of these positive trends can evaporate," she added. Last month, Newsweek broke down how birth rates have changed across all age groups over the past 50 years. While mothers between the ages of 50 and 54 had no babies in 1975, this number gradually increased to more than 100 over the years and was 159 in 2024. People in their twenties have had fewer babies, often delaying children to their thirties, which has meant the number of births in this age group has increased. America is one of many countries around the world struggling with falling birth rates. Fertility rates are projected to average 1.6 births per woman over the next three decades, according to the Congressional Budget Office's latest forecast released this year. This number is well below the replacement level of 2.1 births per woman required to maintain a stable population without immigration. Many trying to tackle this issue have focused on public health policies and financial plans, often citing the 2008 financial crisis, its effect on housing, inflation and pay as a major contributor to why people delay having children, have fewer of them or to not have them at all. The Donald Trump administration has made this issue one of its priorities, with the White House exploring the possibility of giving women a "baby bonus" of $5,000, according to an April New York Times report. Related Articles Couple Living 'Best Life' As Kids Enter High School, Then Comes the TwistWhat Mom Does To Keep 13-Year-Old Safe While She Runs: 'This Is America?'Millennial Man Rediscovers 2008 Photos-No One Prepared for What They ShowGen Zer Loves New Tattoo, Then She Realizes Something: 'What Do I Do?' 2025 NEWSWEEK DIGITAL LLC.
